|
ATCC
normal human gingival keratinocytes Normal Human Gingival Keratinocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/Primary+Gingival+Keratinocytes%3B+Normal%2C+Human/pmc12521062-73-0-13 Average 94 stars, based on 1 article reviews
normal human gingival keratinocytes - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
ATCC
normal human neonatal keratinocytes ![]() Normal Human Neonatal Keratinocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/Primary+Epidermal+Keratinocytes%3B+Normal%2C+Human%2C+Neonatal+Foreskin/pmc06754567-132-2-30 Average 99 stars, based on 1 article reviews
normal human neonatal keratinocytes - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
human skin keratinocytes ![]() Human Skin Keratinocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/Primary+Epidermal+Keratinocytes%3B+Normal%2C+Human%2C+Adult/pm32582096-90-14-18 Average 99 stars, based on 1 article reviews
human skin keratinocytes - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
product atcc pcs 200 010 ![]() Product Atcc Pcs 200 010, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/Primary+Epidermal+Keratinocytes%3B+Normal%2C+Human%2C+Neonatal/us09655930-72-16-17 Average 94 stars, based on 1 article reviews
product atcc pcs 200 010 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
ATCC
human epidermal keratinocytes ![]() Human Epidermal Keratinocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/Primary+Epidermal+Keratinocytes%3B+Normal%2C+Human%2C+Adult/us10562894-799-30-33 Average 95 stars, based on 1 article reviews
human epidermal keratinocytes - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
PromoCell
primary normal human epidermal keratinocytes nheks ![]() Primary Normal Human Epidermal Keratinocytes Nheks, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/NHEK-c+Human+Epidermal+Keratinocytes/bio_rxiv__64898__2026__04__08__717198-124-0-18 Average 95 stars, based on 1 article reviews
primary normal human epidermal keratinocytes nheks - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
PromoCell
primary human cell culture primary human epidermal keratinocytes phkc ![]() Primary Human Cell Culture Primary Human Epidermal Keratinocytes Phkc, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/NHEK%2Ef-c+Human+Epidermal+Keratinocytes/pmc05176004__mmc1-58-0-20 Average 95 stars, based on 1 article reviews
primary human cell culture primary human epidermal keratinocytes phkc - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
PromoCell
c 12011 sickingenstr ![]() C 12011 Sickingenstr, supplied by PromoCell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/NHEK%2Ef-c+Human+Epidermal+Keratinocytes+isolated+in+Growth+Medium+3/pmc12701548-41-9-8 Average 93 stars, based on 1 article reviews
c 12011 sickingenstr - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
ScienCell
human epidermal keratinocytes (heks) ![]() Human Epidermal Keratinocytes (Heks), supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/human+primary+neonatal+keratinocytes/pm22609345-41-0-21 Average 90 stars, based on 1 article reviews
human epidermal keratinocytes (heks) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
PELOBIOTECH GmbH
primary human keratinocytes ![]() Primary Human Keratinocytes, supplied by PELOBIOTECH GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/primary+human+keratinocytes/pm37981221-48-34-39 Average 90 stars, based on 1 article reviews
primary human keratinocytes - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
CELLnTEC Advanced Cell Systems AG
normal human keratinocytes hpek ![]() Normal Human Keratinocytes Hpek, supplied by CELLnTEC Advanced Cell Systems AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/human+primary+epidermal+keratinocytes+hpek+50/pm32949447-39-0-11 Average 90 stars, based on 1 article reviews
normal human keratinocytes hpek - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
BioWhittaker Molecular Applications
human primary epidermal keratinocytes ![]() Human Primary Epidermal Keratinocytes, supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+primary+keratinocytes/human+primary+epidermal+keratinocytes/10__1111_slash_j__0022___202x__2004__22731__x-141-0-7 Average 90 stars, based on 1 article reviews
human primary epidermal keratinocytes - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Toxicology and applied pharmacology
Article Title: Monoubiquitinated γ-H2AX: abundant product and specific biomarker for non-apoptotic DNA double-strand breaks
doi: 10.1016/j.taap.2018.07.007
Figure Lengend Snippet: Panels A-C used antibodies #1. (A) Impact of gel polyacrylamide percentage and transfer conditions to PVDF membranes. Treatments of H460 cells: 6 h with 3 mM hydroxyurea (HU), 6 or 16 h with 5 μM aphidicolin (Aphi) or 1 h with 5 μM bleomycin (Bleo). All γ-H2AX images had 5 s film exposures. (B) Ethanol effect in semi-dry transfer. IMR90 cells were treated with 40 μM etoposide (Eto) for 1 h. (C) Comparison of wet (pH 8.2 and pH 8.8) and semi-dry transfers using 12% ethanol-containing buffers (10 s film exposures for all γ-H2AX images). IMR90 cells were treated with 40 μM etoposide for 1 h. (D) Effectiveness of different antibodies using semi-dry transfer with 12% ethanol. Normal human keratinocytes were treated for 1 h with 30 μM etoposide or 0.5 μM bleomycin. Antibodies #1–3: 1:1000 dilutions and 5 s exposures, antibody #4: 1:1000 dilution and 60 s exposure. (E) Comparison of antibodies #1 and #5 (both at 1:1000 dilutions) in H460 cells treated with bleomycin for 1 h. (F) γ-H2AX blot (Ab#1) in control and H2AX-depleted IMR90 cells treated with 100 μM etoposide for 1h.
Article Snippet: IMR90, WI38,
Techniques: Comparison, Control
Journal: bioRxiv
Article Title: Comparative analysis of varicella-zoster virus and herpes simplex virus 1 interaction with epidermal terminal differentiation in primary human keratinocytes models of differentiation
doi: 10.64898/2026.04.08.717198
Figure Lengend Snippet: A. Schematic of epidermal differentiation and the differentiation stages at which viral infections were implemented; undifferentiated (Undiff.), early differentiated (Early diff.) and late differentiated (Late diff.). B. Schematic of plan of infection with VZV at MOI 0.1 of Undiff., Early diff. and Late diff. NHEKs. “Undiff.”, “Early diff.” and “Late diff.” labelling refers to the state of NHEKs differentiation at the time of infection (day 0). The “Undiff.” condition includes the NHEKs undergoing differentiation by calcium switch after infection (Differentiating_sync.) C. Analysis by qPCR of cell-associated VZV genome copy number normalised to number of cells, upon infection with VZV of Undiff., Early diff. and Late diff. NHEKs, and evaluated at 24h and 120h p.i. The data are generated from quantification of the VZV ORF31 gene (gB) normalised to RPP30 gene (host internal control) and are reported as the mean of three technical replicates. D. Analysis by qPCR of cell-associated VZV genome copy number normalised to number of cells upon infection with VZV of Late diff. NHEKs, and evaluated at 5 days (120h) and 7 days p.i. The data are generated from quantification of the VZV ORF31 gene (gB) normalised to RPP30 gene (host internal control) and are reported as the mean of three technical replicates. E. Analysis by qRT-PCR of ORFC2 (encoding the IE62 protein) and ORFC8 (encoding the gE protein) in VZV infection of Undiff., Early diff. and Late diff. NHEKs, and reported at 24h and 120h p.i. The data are reported as mean of 2 -dCT of three technical replicates, where the normalisation was performed against GAPDH . F. Analysis by qRT-PCR of ORFC2 and ORFC8 in VZV infection of Late diff. NHEKs, and evaluated at 120h and 7 days p.i. The data are reported as mean of 2 -dCT of three technical replicates, where the normalisation was performed against GAPDH . G. Western Blotting analysis of gE and IE62 expression at 120h p.i. following infection of Undiff., Early diff. and Late diff. NHEKs with VZV. GAPDH was used as loading control . H. Fast red staining of gE at 120h p.i. following infection of Undiff., Early diff. and Late diff. NHEKs with VZV. Graph shows the quantification of number of VZV plaques in at least two fields of view per condition and is reported as mean ± SD. I. IE62 and gE (green) immunofluorescence staining of Undiff. and Early diff. NHEKs infected with VZV and analysed at 120h p.i. DAPI (blue) was used for staining of nuclei. Graphs show quantification of integrated density of IE62 and gE signals in at least two fields of view per condition ± SD. Data in C., E. and G. are representative of n=3 independent experiments (for the Undiff. and Early Diff. conditions), data in I. are representative of n=2 independent experiments. Statistical significance was evaluated in H. by one-way ANOVA with Dunnett’s multiple comparisons test, in I. by two-tailed t test. Statistical significance is indicated as *P< 0.05, **P< 0.01, ***P< 0.001. Scale bar, 50 μm. Undiff., undifferentiated; Early diff., early differentiated; Late diff., late differentiated; p.i., post infection; NHEKs, normal human epidermal keratinocytes.
Article Snippet:
Techniques: Infection, Generated, Control, Quantitative RT-PCR, Western Blot, Expressing, Staining, Immunofluorescence, Two Tailed Test
Journal: bioRxiv
Article Title: Comparative analysis of varicella-zoster virus and herpes simplex virus 1 interaction with epidermal terminal differentiation in primary human keratinocytes models of differentiation
doi: 10.64898/2026.04.08.717198
Figure Lengend Snippet: A. Schematic of plan of infection with HSV-1 at MOI 0.005 of undifferentiated (Undiff.), early differentiated (Early diff.) and late differentiated (Late diff.) NHEKs. “Undiff.”, “Early diff.” and “Late diff.” labelling refers to the state of NHEKs differentiation at the time of infection (day 0). The “Undiff.” condition includes the NHEKs undergoing spontaneous asynchronous differentiation after infection (Differentiating_async.) B. Analysis by qPCR of cell-associated HSV-1 genome copy number normalised to number of cells, upon infection with HSV-1 of Undiff., Early diff. and Late diff. NHEKs, and evaluated at 24h, 48h and 72h p.i. The data are generated from quantification of the HSV-1 UL27 gene (gB) normalised to RPP30 gene (host internal control) and are reported as mean of n=3 independent experiments ± SEM. C. Analysis by qPCR of cell-associated HSV-1 genome copy number normalised to number of cells, upon infection with HSV-1 of Late diff. NHEKs, and reported at 72h and 120h p.i. The data are generated from quantification of the HSV-1 UL27 gene (gB) normalised to RPP30 gene (host internal control) and are reported as the mean of three technical replicates. D. ICP0 (pink) immunofluorescence staining of Undiff., Early diff. and Late diff. NHEKs infected with HSV-1 and analysed at 4h, 24h and 72h p.i. The reported images include GFP (green) signal deriving from the GFP protein tagged to the late HSV-1 tegument protein UL46 and DAPI (grey) staining of nuclei. E. Analysis by qRT-PCR analysis of RL2 gene (encoding the ICP0 protein) and UL48 gene (encoding the VP16 protein) expression in HSV-1 infection of Undiff., Early diff. and Late diff. NHEKs, and reported at 24h, 48h and 72h p.i. The data are reported as mean of 2 -dCT of n=3 independent experiments ± SEM, where the normalisation was performed against GAPDH . F. Western Blotting analysis of ICP0 and VP16 expression at 24h, 48h and 72h p.i. following infection of Undiff., Early diff. and Late diff. NHEKs with HSV-1. GAPDH was used as loading control. Data are representative of n=4 independent experiments (Undiff. condition), n=3 independent experiments (Early diff. condition) and n=2 independent experiments (Late diff. condition). G. Schematic of the model of HSV-1 infection implemented in undifferentiated NHEKs, which either remained undifferentiated throughout the infection and until the last time point (72h) (Undifferentiated) or started undergoing spontaneous differentiation during the last time points of infection (Differentiating_async). H. Analysis by qRT-PCR of KRT5 and KRT10 mRNAs in uninfected NHEKs at 72h confirming the undifferentiated and differentiating status of the keratinocytes. The data are reported as fold change (FC) (2 -ddCT ) to the undifferentiated condition and are the mean of three technical replicates, where the normalisation was performed against GAPDH . I. Keratinocytes where infected when undifferentiated and then either maintained their undifferentiated status throughout the infection (Undifferentiated) or were allowed to spontaneously differentiate by 72h p.i. (Differentiating). Cell-associated HSV-1 genome copy number was analysed at 72h p.i. in both conditions. The data are generated from quantification of the HSV-1 UL27 gene (gB) normalised to RPP30 gene (host internal control), are reported as the mean of three technical replicates and are representative of n=3 independent experiments. J. Anlysis by qRT-PCR of RL2 and UL48 mRNAs in HSV-1 infected Undifferentiated and Differentiating NHEKs at 72h p.i. The data are reported as mean of 2 -dCT of three technical replicates, where the normalisation was performed against GAPDH . Data are representative of n=3 independent experiments. Statistical significance was evaluated in B. and E. by 2way ANOVA with Tukey’s multiple comparisons test and indicated as *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001. In D. , dotted lines mark nuclei at 4h p.i. Insets contain zoomed-in areas of the ICP0 signal inside the nuclei at 4h p.i. Scale bar, 10 μm. Undiff., undifferentiated; Early diff., early differentiated; Late diff., late differentiated; p.i., post infection; NHEKs, normal human epidermal keratinocytes.
Article Snippet:
Techniques: Infection, Generated, Control, Immunofluorescence, Staining, Quantitative RT-PCR, Expressing, Western Blot
Journal: bioRxiv
Article Title: Comparative analysis of varicella-zoster virus and herpes simplex virus 1 interaction with epidermal terminal differentiation in primary human keratinocytes models of differentiation
doi: 10.64898/2026.04.08.717198
Figure Lengend Snippet: A. Analysis of qRT-PCR expression of KRT10 (encoding the K10 protein) in VZV infection (at the MOI of 0.1) of Undiff., Early diff. and Late diff. NHEKs, and reported at 24h, 120h p.i. and at 7 days p.i. (in the Late diff.). The data are reported as fold change (FC) (2 -ddCT ) to each uninfected control from the mean of three technical replicates, where the normalisation was performed against GAPDH . Similar trends were observed in other 2 independent experiments for the Undiff. and Early Diff. conditions using different MOIs. B. Western Blotting analysis of K10 expression at 120h p.i. following infection of Undiff., Early diff. and Late diff. NHEKs with VZV at the MOI of 0.1. GAPDH was used as loading control. Numbers at the bottom of the blots indicate K10 densitometry expressed as fold change to each uninfected control, following normalisation against GAPDH . Data are representative of n=3 independent experiments for the Undiff. and Early Diff. conditions. C. K10 (red) and gE (green) immunofluorescence staining of Undiff., Early diff. and Late diff. NHEKs infected with VZV at the MOI of 0.1 and analysed at 120h p.i. DAPI (blue) was used for staining of nuclei. Data are representative of n=2 independent experiments for the Undiff. and Early Diff. conditions. D. Analysis by qRT-PCR of KRT10 mRNA expression in HSV-1 infection (at the MOI of 0.005) of Undiff., Early diff. and Late diff. NHEKs, and reported at 24h, 48h and 72h p.i. The data are reported as fold change (FC) (2 -ddCT ) to each uninfected control from the mean of n=3 independent experiments ± SEM, where the normalisation was performed against GAPDH . E. Western Blotting analysis of K10 expression at 24h, 48h and 72h p.i. following infection of Undiff., Early diff. and Late diff. NHEKs with HSV-1 at the MOI of 0.005. GAPDH was used as loading control. Data are representative of n=4 independent experiments for the Undiff. condition, n=3 independent experiments for the Early diff. condition and n=2 independent experiments for the Late diff. condition. In the Undiff. and Early diff. conditions 16μg of proteins were run. In the Late diff. condition 5μg of proteins were run to compensate for the high concentration of K10 in this condition. F. K10 (yellow) and VP16 (pink) immunofluorescence staining, of Undiff., Early diff. and Late diff. NHEKs infected with HSV-1 at the MOI of 0.005, and analysed at 72h p.i. DAPI (blue) was used for staining of nuclei. G. Analysis by qRT-PCR at 72h p.i. of expression of KRT10 mRNA in HSV-1 infection (at the MOI of 0.005) of Undiff. NHEKs treated either with foscarnet or with vehicle alone at the time of infection. The data are reported as fold change (FC) (2 -ddCT ) to each uninfected control, from the mean of three technical replicates, where the normalisation was performed against GAPDH . The data are representative of n=2 independent experiments. H. Keratin 10 (green) and gE (red) immunofluorescence staining of ex-vivo human skin tissues infected with VZV (10 4 PFU) and analysed 11 days p.i. DAPI (blue) was used for staining of nuclei. I. Keratin 10 (red) immunofluorescence staining of ex-vivo human skin tissues infected with HSV-1 (10 4 PFU) and analysed 11 days p.i. GFP signal (green) marks the expression of the GFP-tagged late HSV-1 protein UL46. DAPI (blue) was used for staining of nuclei. In H. and I. dotted lines indicate the epidermal-dermal junction. Scale bars, 50 μm. Undiff., undifferentiated; Early diff., early differentiated; Late diff., late differentiated; p.i., post infection; UNINF, uninfected.
Article Snippet:
Techniques: Quantitative RT-PCR, Expressing, Infection, Control, Western Blot, Immunofluorescence, Staining, Concentration Assay, Ex Vivo